Cabergoline and Coasting to Prevent OHSS — OHSS

OHSS Clinical Trial

Official title:
Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial

Status Completed

Clinical Trial Summary

The effectiveness of cabergoline to prevent moderate-severe OHSS to coasting.

Clinical Trial Description

To randomly compare three study groups under a high risk of developing OHSS to one of three arms of management, either coasting for 1 to 3 days or receiving cabergoline for 8 days or coasting for 1 day plus receiving cabergoline for 8 days in ICSI patients following the long luteal GnRH agonist protocol. ;

Study Design

Related Conditions & MeSH terms

OHSS
Ovarian Hyperstimulation Syndrome

Clinical Trial Details

NCT number	NCT01984320
Study type	Interventional
Source	Cairo University
Contact
Status	Completed
Phase	N/A
Start date	October 2013
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02875587` - Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome	Phase 2
Recruiting	`NCT02358421` - Prediction of High Ovarian Response After Assisted Reproductive Techniques	N/A
Completed	`NCT01709942` - Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)	Phase 3
Completed	`NCT02148393` - Implantation Enhancement by Elective Cryopreservation of All Viable Embryos	N/A
Recruiting	`NCT02461875` - Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome	Phase 2